Oncomed Pharmaceuticals’ (OMED) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Oncomed Pharmaceuticals (NASDAQ:OMED) in a research note released on Friday.

Other research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Oncomed Pharmaceuticals from a hold rating to a buy rating and set a $5.50 price target on the stock in a research report on Wednesday, November 8th. Cantor Fitzgerald set a $6.00 price target on shares of Oncomed Pharmaceuticals and gave the company a hold rating in a research report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $5.81.

Oncomed Pharmaceuticals (OMED) remained flat at $$2.16 on Friday. 122,141 shares of the stock traded hands, compared to its average volume of 224,816. Oncomed Pharmaceuticals has a 1 year low of $1.74 and a 1 year high of $10.89. The company has a market capitalization of $81.77, a P/E ratio of -1.14 and a beta of 2.24.

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMED. Hodges Capital Management Inc. raised its position in Oncomed Pharmaceuticals by 155.9% in the third quarter. Hodges Capital Management Inc. now owns 25,592 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 15,592 shares during the period. BlueCrest Capital Management Ltd bought a new stake in Oncomed Pharmaceuticals in the fourth quarter worth about $133,000. Paloma Partners Management Co bought a new stake in Oncomed Pharmaceuticals in the fourth quarter worth about $135,000. Virtu Financial LLC bought a new stake in Oncomed Pharmaceuticals in the fourth quarter worth about $170,000. Finally, Goldman Sachs Group Inc. raised its position in Oncomed Pharmaceuticals by 89.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 52,106 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 24,653 shares during the period. 36.19% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/24/oncomed-pharmaceuticals-omed-neutral-rating-reaffirmed-at-hc-wainwright.html.

Oncomed Pharmaceuticals Company Profile

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).

Analyst Recommendations for Oncomed Pharmaceuticals (NASDAQ:OMED)

Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply